These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15504303)

  • 1. [The role of enterogenous endotoxemia in the pathogenesis of non-alcoholic steatohepatitis].
    Zhao LF; Jia JM; Han DW
    Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):632. PubMed ID: 15504303
    [No Abstract]   [Full Text] [Related]  

  • 2. [Role of peroxisome proliferator activated receptor alpha in the pathogenesis of nonalcoholic steatohepatitis].
    Zhao CY; Deng ZJ; Zhou JY
    Zhonghua Gan Zang Bing Za Zhi; 2006 Feb; 14(2):146-7. PubMed ID: 16494792
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis.
    Wigg AJ; Roberts-Thomson IC; Dymock RB; McCarthy PJ; Grose RH; Cummins AG
    Gut; 2001 Feb; 48(2):206-11. PubMed ID: 11156641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease.
    Gulsen M; Yesilova Z; Bagci S; Uygun A; Ozcan A; Ercin CN; Erdil A; Sanisoglu SY; Cakir E; Ates Y; Erbil MK; Karaeren N; Dagalp K
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1448-55. PubMed ID: 16105135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Obesity and non-alcoholic steatohepatitis].
    Méndez-Sánchez N; Chávez-Tapia NC; Uribe M
    Gac Med Mex; 2004; 140 Suppl 2():S67-72. PubMed ID: 15641474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of NASH: animal models.
    London RM; George J
    Clin Liver Dis; 2007 Feb; 11(1):55-74, viii. PubMed ID: 17544972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked elevation of serum mitochondrion-derived markers in mild models of non-alcoholic steatohepatitis in rats.
    Murayama H; Ikemoto M; Nagata A
    J Gastroenterol Hepatol; 2009 Feb; 24(2):270-7. PubMed ID: 18823438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Non-alcoholic steatohepatitis].
    Moreno Sánchez D
    An Med Interna; 1989 Feb; 6(2):100-3. PubMed ID: 2491061
    [No Abstract]   [Full Text] [Related]  

  • 9. Pathogenesis of non-alcoholic steatohepatitis: human data.
    Edmison J; McCullough AJ
    Clin Liver Dis; 2007 Feb; 11(1):75-104, ix. PubMed ID: 17544973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feeding a corn oil/sucrose-enriched diet enhances steatohepatitis in sedentary rats.
    Rivera CA; Abrams SH; Tcharmtchi MH; Allman M; Ziba TT; Finegold MJ; Smith CW
    Am J Physiol Gastrointest Liver Physiol; 2006 Feb; 290(2):G386-93. PubMed ID: 16223947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic steatohepatitis in children.
    Roberts EA
    Clin Liver Dis; 2007 Feb; 11(1):155-72, x. PubMed ID: 17544977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-Allylsecoboldine as a novel agent prevents acute renal failure during endotoxemia.
    Chiao CW; Lee SS; Wu CC; Su MJ
    Eur J Pharmacol; 2006 Mar; 535(1-3):291-300. PubMed ID: 16545365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease: interleukin-10 to tumor necrosis factor-alpha ratio in steatohepatitis.
    Hashem RM; Mahmoud MF; El-Moselhy MA; Soliman HM
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):995-1001. PubMed ID: 18787467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alcoholic and nonalcoholic steatohepatitis: the same disease! I. Diagnosis and mechanisms].
    Spahr L; Rubbia-Brandt L; Hadengue A
    Rev Med Suisse; 2005 Sep; 1(31):2026-8, 2030-1. PubMed ID: 16212004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model.
    Yalniz M; Bahcecioglu IH; Kuzu N; Poyrazoglu OK; Bulmus O; Celebi S; Ustundag B; Ozercan IH; Sahin K
    J Gastroenterol Hepatol; 2007 Nov; 22(11):2009-14. PubMed ID: 17914984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-alcoholic steatohepatitis: natural history and diagnosis].
    Larrey D
    Gastroenterol Clin Biol; 2003; 27(8-9):793-8. PubMed ID: 14586250
    [No Abstract]   [Full Text] [Related]  

  • 17. The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis.
    Miele L; Forgione A; Hernandez AP; Gabrieli ML; Vero V; Di Rocco P; Greco AV; Gasbarrini G; Gasbarrini A; Grieco A
    Eur Rev Med Pharmacol Sci; 2005; 9(5):273-7. PubMed ID: 16231589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator.
    Yu J; Ip E; Dela Peña A; Hou JY; Sesha J; Pera N; Hall P; Kirsch R; Leclercq I; Farrell GC
    Hepatology; 2006 Apr; 43(4):826-36. PubMed ID: 16557554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-alcoholic steatohepatitis].
    García Monzón C
    Gastroenterol Hepatol; 2001 Oct; 24(8):395-402. PubMed ID: 11674960
    [No Abstract]   [Full Text] [Related]  

  • 20. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
    Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
    Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.